Comparison of Outcomes after Reperfusion Therapy between In-Hospital and Out-of-Hospital Stroke Patients

2015 ◽  
Vol 40 (1-2) ◽  
pp. 28-34 ◽  
Author(s):  
Joonsang Yoo ◽  
Dongbeom Song ◽  
Kijeong Lee ◽  
Young Dae Kim ◽  
Hyo Suk Nam ◽  
...  
Keyword(s):  
Hospital Mortality ◽  
Symptom Onset ◽  
Reperfusion Therapy ◽  
University Hospital ◽  
Time Interval ◽  
Time Intervals ◽  
Symptomatic Intracerebral Hemorrhage ◽  
All Cause Mortality ◽  
Tissue Plasminogen ◽  
Favorable Functional Outcome

Background: Patients may experience stroke while being admitted to the hospital (in-hospital stroke (IHS)) and they may be important candidates for reperfusion therapy. IHS patients may have various comorbidities and show worse outcomes compared with patients with an out-of-hospital stroke (OHS). On the other hand, the time from onset to treatment may be shorter in IHS patients than OHS patients. Most outcome studies of reperfusion therapy have been based on findings in OHS patients, and little information is currently available regarding outcomes of IHS, whether the outcomes differ between patients with IHS and those with OHS who receive reperfusion therapy. Methods: This is a retrospective observational study using prospectively registered data. Consecutive patients who underwent the reperfusion therapy (intravenous (IV), intra-arterial (IA), or combined IV and IA) between July 2002 and June 2014 in a university hospital were included for this study. We compared the demographics, time interval from symptom onset to treatment, and outcomes between IHS and OHS patients and analyzed the factors associated with in-hospital mortality. Results: A total of 686 patients received the reperfusion therapy during the study period. Of them, 256 (37.3%) patients received the IV tissue plasminogen activator (t-PA) therapy only, 243 (35.4%) patients received the IA therapy only, and 187 (27.3%) patients received the combined IV and IA therapy. Among these, 104 (15.2%) were IHS patients. The time intervals from symptom onset to IV t-PA administration (87.5 ± 48.4 vs. 113.4 ± 38.3 min, p < 0.001) and IA puncture (221.8 ± 195.0 vs. 343.6 ± 155.4 min, p < 0.001) were shorter for IHS than OHS. The rates of successful recanalization and symptomatic intracerebral hemorrhage, and the favorable functional outcome at 3 months were similar between the groups. In-hospital all-cause mortality was higher in IHS than OHS (16.3 vs. 8.4%, p = 0.019), but after adjustment, IHS was not an independent factor. The stroke mortality did not differ between the groups (9.6 vs. 6.9%, p = 0.432). Conclusions: Although IHS patients more frequently had comorbid diseases and higher overall in-hospital mortality, the standard outcomes of the reperfusion therapy were similar between IHS and OHS patients, which might be, in part, ascribed to the shorter interval from symptom onset to treatment in IHS. Considering a substantial portion of IHS patients, we should pay more attention to these patients.

scholarly journals The role of process mining tools in STEMI networks: where should we build a new primary PCI centre?

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
J Borges-Rosa ◽  
M Oliveira-Santos ◽  
M Simoes ◽  
P Carvalho ◽  
G Ibanez-Sanchez ◽  
...  
Keyword(s):  
Time Delay ◽  
Hospital Mortality ◽  
Median Time ◽  
Symptom Onset ◽  
Process Mining ◽  
Reperfusion Therapy ◽  
Primary Pci ◽  
Global Comparison ◽  
Centre Region ◽  
Mining Tools

Abstract Background In ST-segment elevation myocardial infarction (STEMI), time delay between symptom onset and treatment is critical to improve outcome. The expected transport delay between patient location and percutaneous coronary intervention (PCI) centre is paramount for choosing the adequate reperfusion therapy. The “Centre” region of Portugal has heterogeneity in PCI assess due to geographical reasons. Purpose We aimed to explore time delays between regions using process mining (PM) tools. Methods We retrospectively assessed the Portuguese Registry of Acute Coronary Syndromes for patients with STEMI from October 2010 to September 2019, collecting information on geographical area of symptom onset, reperfusion option, and in-hospital mortality. We used a PM toolkit (PM4H – PMApp Version) to build two models (one national and one regional) that represent the flow of patients in a healthcare system, enhancing time differences between groups. One-way analysis of variance was employed for the global comparison of study variables between groups and post hoc analysis with Bonferroni correction was used for multiple comparisons. Results Overall, 8956 patients (75% male, 48% from 51 to 70 years) were included in the national model (Fig. 1A), in which primary PCI was the treatment of choice (73%), with the median time between admission and primary PCI &lt;120 minutes in every region; “Lisboa” and “Centro” had the longest delays, (orange arrows). Fibrinolysis was performed in 4.5%, with a median time delay &lt;1 hour in every region. In-hospital mortality was 5%, significantly higher for those without reperfusion therapy compared to PCI and fibrinolysis (10% vs. 4% vs. 4%, P&lt;0.001). In the regional model (Fig. 1B) corresponding to the “Centre” region of Portugal divided by districts (n=773, 74% male, 47% from 51 to 70 years), only 61% had primary PCI, with “Guarda” (05:04) and “Castelo Branco” (06:50) showing significant longer delays between diagnosis and reperfusion treatment (orange and red arrows, respectively) than “Coimbra” (01:19) (green arrow); only 15% of patients from “Castelo Branco” had primary PCI. Fibrinolysis was chosen in 10% of patients, mostly in “Castelo Branco” (53%), followed by “Guarda” (30%), with a median time delay of 39 and 48 minutes, respectively. Regarding mortality, PCI and fibrinolysis groups had similar death rates while those patients without reperfusion had higher mortality (5% vs. 3% vs. 13%, P=0.001). Conclusion Process mining tools help to understand referencing networks visually, easily highlighting inefficiencies and potential needs for improvement. The “Centre” region of Portugal has lower rates and longer delay to primary PCI partially due to the geographical reasons, with worse outcomes in remote regions. The implementation of a new PCI centre in one of these districts, is critical to offer timely first-line treatment to their population. FUNDunding Acknowledgement Type of funding sources: None. Figure 1

scholarly journals Organizing pneumonia of COVID-19: Time-dependent evolution and outcome in CT findings

PLoS ONE ◽  
2020 ◽  
Vol 15 (11) ◽  
pp. e0240347
Author(s):  
Yan Wang ◽  
Chao Jin ◽  
Carol C. Wu ◽  
Huifang Zhao ◽  
Ting Liang ◽  
...  
Keyword(s):  
Symptom Onset ◽  
Good Prognosis ◽  
Critical Groups ◽  
Time Interval ◽  
Organizing Pneumonia ◽  
Time Intervals ◽  
Ct Findings ◽  
Complete Absorption ◽  
Novel Coronavirus ◽  
Ct Features

Background As a pandemic, a most-common pattern resembled organizing pneumonia (OP) has been identified by CT findings in novel coronavirus disease (COVID-19). We aimed to delineate the evolution of CT findings and outcome in OP of COVID-19. Materials and methods 106 COVID-19 patients with OP based on CT findings were retrospectively included and categorized into non-severe (mild/common) and severe (severe/critical) groups. CT features including lobar distribution, presence of ground glass opacities (GGO), consolidation, linear opacities and total severity CT score were evaluated at three time intervals from symptom-onset to CT scan (day 0–7, day 8–14, day > 14). Discharge or adverse outcome (admission to ICU or death), and pulmonary sequelae (complete absorption or lesion residuals) on CT after discharge were analyzed based on the CT features at different time interval. Results 79 (74.5%) patients were non-severe and 103 (97.2%) were discharged at median day 25 (range, day 8–50) after symptom-onset. Of 67 patients with revisit CT at 2–4 weeks after discharge, 20 (29.9%) had complete absorption of lesions at median day 38 (range, day 30–53) after symptom-onset. Significant differences between complete absorption and residuals groups were found in percentages of consolidation (1.5% vs. 13.8%, P = 0.010), number of involved lobe > 3 (40.0% vs. 72.5%, P = 0.030), CT score > 4 (20.0% vs. 65.0%, P = 0.010) at day 8–14. Conclusion Most OP cases had good prognosis. Approximately one-third of cases had complete absorption of lesions during 1–2 months after symptom-onset while those with increased frequency of consolidation, number of involved lobe > 3, and CT score > 4 at week 2 after symptom-onset may indicate lesion residuals on CT.

Abstract 3174: Intravenous Thrombolysis in 3-4.5 hours: Utilization and outcomes Analysis of the Minnesota Stroke Registry

Stroke ◽  
2012 ◽  
Vol 43 (suppl_1) ◽  
Author(s):  
Wondwossen G Tekle ◽  
Saqib I Chaudry ◽  
Ameer Hassan ◽  
James Peacock ◽  
Kamakshi Lakshiminarayan ◽  
...  
Keyword(s):  
Hospital Mortality ◽  
Symptom Onset ◽  
Time Window ◽  
Intravenous Thrombolysis ◽  
Recombinant Tissue Plasminogen Activator ◽  
Unfavorable Outcome ◽  
Initial Examination ◽  
Stroke Registry ◽  
Symptomatic Intracerebral Hemorrhage ◽  
Assisting Device

Background: The results of the third European Cooperative Acute Stroke Study (ECASS 3) demonstrated that intravenous (IV) thrombolysis for acute ischemic stroke (AIS) improved patient outcomes when administered within 3-4.5 hours (hrs) after symptom onset. We analyzed data from the Minnesota Stroke Registry to assess the rates of IV thrombolytic utilization in this expanded window and examine outcomes of patients treated within the 3-4.5 hrs window. Methods: We identified patients who had received IV recombinant tissue plasminogen activator (rt-PA) at any of the 19 participating hospitals from Jan 1, 2008 till Dec 31, 2010. Treatment groups were those actually treated by IV rt-PA in 0-3 hrs and those treated by IV rt-PA in 3-4.5 hrs. We compared the rates of unfavorable outcome (inability to ambulate independently with or without assisting device at discharge) and in-hospital mortality among patients treated with IV rt-PA within 3-4.5 hrs to those who received IV rt-PA within the conventional 0-3 hrs window. Results: Out of the total 519 patients who received IV rt-PA for AIS, 433 (83%) were treated within 0-3 hrs and 86 (17%) within 3-4.5 hrs. Adjusting for age, sex, and “adverse initial examination findings” (reduced level of consciousness, aphasia, and weakness), there was a trend towards higher rates of unfavorable outcome at discharge among those treated within 3-4.5 hrs compared to those treated within 0-3 hrs time window (Odds ratio [OR], 1.76; 95% confidence interval [CI], 0.95 to 3.26). In hospital mortality did not differ between the 3-4.5 hrs groups and 0-3 hrs groups (OR, 1.05; 95% CI, 0.38 to 2.96). Incidence of symptomatic intracerebral hemorrhage was non-significantly lower in the 3-4.5 hrs group compared to the 0-3 hrs group (2.3% vs.4.6%, p=0.34). Conclusion: Patients who received IV rt-PA within the 3-4.5 hrs window comprised 17% of all IV rt-PA cases treated in the MSR hospitals after guidelines recommended time window expansion. Outcomes of these patients were comparable to those treated within 3 hours of symptom onset.

scholarly journals The role of process mining tools in STEMI networks: where should we build a new primary PCI centre?

2021 ◽  
Vol 2 (4) ◽  
Author(s):  
J Borges-Rosa ◽  
M Oliveira-Santos ◽  
M Simoes ◽  
P Carvalho ◽  
G Ibanez-Sanchez ◽  
...  
Keyword(s):  
Time Delay ◽  
Hospital Mortality ◽  
Median Time ◽  
Symptom Onset ◽  
Process Mining ◽  
Reperfusion Therapy ◽  
Primary Pci ◽  
Global Comparison ◽  
Centre Region ◽  
Mining Tools

Abstract Background In ST-segment elevation myocardial infarction (STEMI), time delay between symptom onset and treatment is critical to improve outcome. The expected transport delay between patient location and percutaneous coronary intervention (PCI) centre is paramount for choosing the adequate reperfusion therapy. The “Centre” region of Portugal has heterogeneity in PCI assess due to geographical reasons. Purpose We aimed to explore time delays between regions using process mining (PM) tools. Methods We retrospectively assessed the Portuguese Registry of Acute Coronary Syndromes for patients with STEMI from October 2010 to September 2019, collecting information on geographical area of symptom onset, reperfusion option, and in-hospital mortality. We used a PM toolkit (PM4H – PMApp Version) to build two models (one national and one regional) that represent the flow of patients in a healthcare system, enhancing time differences between groups. One-way analysis of variance was employed for the global comparison of study variables between groups and post hoc analysis with Bonferroni correction was used for multiple comparisons. Results Overall, 8956 patients (75% male, 48% from 51 to 70 years) were included in the national model (Fig. 1A), in which primary PCI was the treatment of choice (73%), with the median time between admission and primary PCI &lt;120 minutes in every region; “Lisboa” and “Centro” had the longest delays, (orange arrows). Fibrinolysis was performed in 4.5%, with a median time delay &lt;1 hour in every region. In-hospital mortality was 5%, significantly higher for those without reperfusion therapy compared to PCI and fibrinolysis (10% vs. 4% vs. 4%, P&lt;0.001). In the regional model (Fig. 1B) corresponding to the “Centre” region of Portugal divided by districts (n=773, 74% male, 47% from 51 to 70 years), only 61% had primary PCI, with “Guarda” (05:04) and “Castelo Branco” (06:50) showing significant longer delays between diagnosis and reperfusion treatment (orange and red arrows, respectively) than “Coimbra” (01:19) (green arrow); only 15% of patients from “Castelo Branco” had primary PCI. Fibrinolysis was chosen in 10% of patients, mostly in “Castelo Branco” (53%), followed by “Guarda” (30%), with a median time delay of 39 and 48 minutes, respectively. Regarding mortality, PCI and fibrinolysis groups had similar death rates while those patients without reperfusion had higher mortality (5% vs. 3% vs. 13%, P=0.001). Conclusion Process mining tools help to understand referencing networks visually, easily highlighting inefficiencies and potential needs for improvement. The “Centre” region of Portugal has lower rates and longer delay to primary PCI partially due to the geographical reasons, with worse outcomes in remote regions. The implementation of a new PCI centre in one of these districts, is critical to offer timely first-line treatment to their population. Funding Acknowledgement Type of funding sources: None. Figure 1

Abstract 3521: Relationship Between Time from Symptom Onset to Hospital Presentation and Treatment with and Timeliness of Reperfusion Therapy for Patients with ST-Elevation Myocardial Infarction

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Henry H Ting ◽  
Elizabeth H Bradley ◽  
Yongfei Wang ◽  
Brahmajee K Nallamothu ◽  
Jeptha P Curtis ◽  
...  
Keyword(s):  
Symptom Onset ◽  
Linear Models ◽  
Reperfusion Therapy ◽  
Subsequent Treatment ◽  
Time Intervals ◽  
St Elevation ◽  
Door To Balloon ◽  
The Relationship ◽  
Therapy Quality

Background: Whether patients with STEMI with longer times from symptom onset to hospital presentation are less likely to be treated with any reperfusion therapy or treated with less urgency resulting in longer door-to-balloon and door-to-needle times is not known. The relationship between delay in hospital presentation and the quality of reperfusion therapy for patients with STEMI has not been examined Methods: We constructed 3 cohorts of STEMI patients to analyze use of any reperfusion (n=440,398), door-to-balloon time (n=67,207), and door-to-drug time (n=183,441) as a function of delay in hospital presentation. We constructed multivariable generalized linear models for each outcome to estimate the associations between delay in hospital presentation adjusted for all patient and hospital characteristics. Results: In adjusted analysis, longer times from symptom onset to hospital presentation was associated with lower use of any reperfusion therapy (p<0.0001 for trend). For early presenters with times of ≤1 hour, >1 to 2 hours, and >2 to 3 hours, 77%, 77%, and 73% of patients received any reperfusion therapy, respectively, and late presenters with times >9 to 10 hours, >10 to 11 hours, and >11 to 12 hours were treated with any reperfusion therapy in 53%, 50%, and 46%, respectively. Delay in hospital presentation was associated with longer drug-to-balloon and door-to-drug times (p<0.0001 for trend). For time intervals of ≤ 1 hour, >1 to 2 hours, >2 to 3 hours, >9 to 10 hours, >10 to 11 hours, and >11 to 12 hours, patients with STEMI were treated with door-to-balloon times of 99, 101, 106, 123, 125, and 123 minutes respectively. For delay time intervals of ≤ 1 hour, >1 to 2 hours, >2 to 3 hours, >9 to 10 hours, >10 to 11 hours, and >11 to 12 hours, patients were treated with door-to-drug times of 32, 34, 36, 46, 44, and 46 minutes, respectively. Conclusions: Longer time from symptom onset to hospital presentation has important implications for subsequent treatment and was associated with lower use of any reperfusion therapy and longer door-to-balloon and door-to-drug times. Longer delay in hospital presentation is associated with worse system performance for reperfusion therapy quality and represents an opportunity to improve quality of care for STEMI patients.

scholarly journals Factors Determining Retreatment Time Interval of Rituximab in Korean Patients With Rheumatoid Arthritis

2021 ◽  
Vol 8 ◽  
Author(s):  
Ji-Won Kim ◽  
Ju-Yang Jung ◽  
Kichul Shin ◽  
Chang-Hee Suh ◽  
Hyoun-Ah Kim
Keyword(s):  
Rheumatoid Arthritis ◽  
Biologic Agents ◽  
University Hospital ◽  
Time Interval ◽  
Time Intervals ◽  
Factors Associated ◽  
On Demand ◽  
Persistence Rates ◽  
The Mean

Unlike other biologic agents for rheumatoid arthritis (RA) that are administered at regular intervals even without flare, rituximab can be administered according to the timing of retreatment determined by the physician. Recently, there has been a tendency to prefer on-demand administration for disease flares rather than regular retreatment. We aimed to investigate the retreatment patterns of rituximab in patients with RA and to identify factors associated with extension of the time interval between retreatment courses. This study included RA patients on rituximab treatment who were enrolled in the Korean Rheumatology Biologics registry (KOBIO) or treated at Ajou University Hospital. Previous or current concomitant conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), corticosteroids, number of previous biologic agents, withdrawal, and time intervals of rituximab retreatment were collected. In case of treatment failure, the reasons such as lack of efficacy, adverse events, and others, were also identified. A total of 82 patients were enrolled. The mean follow-up period from the first cycle of rituximab was 46.1 months, and the mean interval between the retreatment courses was 16.3 months. The persistent rates of rituximab after 5 years was 72.4%. Concomitant use of at least two csDMARDs (β = 4.672; 95% CI: 0.089–9.255, p = 0.046) and concomitant use of corticosteroids (β = 7.602; 95% CI: 0.924–14.28, p = 0.026) were independent factors for extending the time interval between the retreatment courses. In conclusion, RA patients treated with rituximab in Korea show high persistence rates. Concomitant use of two or more csDMARDs and concomitant use of corticosteroids with rituximab are associating factors of extending the retreatment time interval. These findings should be considered when selecting rituximab as a treatment for patients with RA.

Female Stroke

Stroke ◽  
2021 ◽  
Vol 52 (2) ◽  
pp. 406-415
Author(s):  
Anna K. Bonkhoff ◽  
André Karch ◽  
Ralph Weber ◽  
Jürgen Wellmann ◽  
Klaus Berger
Keyword(s):  
Sex Differences ◽  
Hospital Mortality ◽  
Functional Outcome ◽  
Intravenous Thrombolysis ◽  
Time Interval ◽  
Stroke Severity ◽  
Stroke Registry ◽  
Logistic Regression Models ◽  
Female Patients ◽  
Favorable Functional Outcome

Background and Purpose: Men and women are differently affected by acute ischemic stroke (AIS) in many aspects. Prior studies on sex disparities were limited by moderate sample sizes, varying years of data acquisition, and inconsistent inclusions of covariates leading to controversial findings. We aimed to analyze sex differences in AIS severity, treatments, and early outcome and to systematically evaluate the effect of important covariates in a large German stroke registry. Methods: Analyses were based on the Stroke Registry of Northwestern Germany from 2000 to 2018. We focused on admission-stroke severity and disability, acute recanalization treatment, and early stroke outcomes. Potential sex divergences were investigated via odds ratio (OR) using logistic regression models. Covariates were introduced in 3 steps: (1) base models (age and admission year), (2) partially adjusted models (additionally corrected for acute stroke severity and recanalization treatment), (3) fully adjusted models (additionally adjusted for onset-to-admission time interval, prestroke functional status, comorbidities, and stroke cause). Models were separately fitted for the periods 2000 to 2009 and 2010 to 2018. Results: Data from 761 106 patients with AIS were included. In fully adjusted models, there were no sex differences with respect to treatment with intravenous thrombolysis (2000–2009: OR, 0.99 [95% CI, 0.94–1.03]; 2010–2018: OR, 1.0 [0.98–1.02]), but women were more likely to receive intraarterial therapy (2010–2018: OR, 1.12 [1.08–1.15]). Despite higher disability on admission (2000–2009: OR, 1.10 [1.07–1.13]; 2010–2018: OR, 1.09 [1.07–1.10]), female patients were more likely to be discharged with a favorable functional outcome (2003–2009: OR, 1.05 [1.02–1.09]; 2010–2018: OR, 1.05 [1.04–1.07]) and experienced lower in-hospital mortality (2000–2009: OR, 0.92 [0.86–0.97]; 2010–2018: OR, 0.91 [0.88–0.93]). Conclusions: Female patients with AIS have a higher chance of receiving intraarterial treatment that cannot be explained by clinical characteristics, such as age, premorbid disability, stroke severity, or cause. Women have a more favorable in-hospital recovery than men because their higher disability upon admission was followed by a lower in-hospital mortality and a higher likelihood of favorable functional outcome at discharge after adjustment for covariates.

scholarly journals Organizing Pneumonia of COVID-19: Time-dependent Evolution and Outcome in CT Findings

2020 ◽  
Author(s):  
Yan Wang ◽  
Chao Jin ◽  
Carol C. Wu ◽  
Huifang Zhao ◽  
Ting Liang ◽  
...  
Keyword(s):  
Symptom Onset ◽  
Good Prognosis ◽  
Critical Groups ◽  
Time Interval ◽  
Organizing Pneumonia ◽  
Time Intervals ◽  
Ct Findings ◽  
Complete Absorption ◽  
Novel Coronavirus ◽  
Ct Features

AbstractObjectiveAs a pandemic, a most-common pattern resembled organizing pneumonia (OP) has been identified by CT findings in novel coronavirus disease (COVID-19). We aimed to delineate the evolution of CT findings and outcome in OP of COVID-19.Materials and Methods106 COVID-19 patients with OP based on CT findings were retrospectively included and categorized into non-severe (mild/common) and severe (severe/critical) groups. CT features including lobar distribution, presence of ground glass opacities (GGO), consolidation, linear opacities and total severity CT score were evaluated at three time intervals from symptom-onset to CT scan (day 0-7, day 8-14, day>14). Discharge or adverse outcome (admission to ICU or death), and pulmonary sequelae (complete absorption or lesion residuals) on CT after discharge were analyzed based on the CT features at different time interval.Results79(74.5%) patients were non-severe and 103(97.2%) were discharged at median day 25 (range, day 8-50) after symptom-onset. Of 67 patients with revisit CT at 2-4 weeks after discharge, 20(29.9%) had complete absorption of lesions at median day 38 (range, day 30-53) after symptom-onset. Significant differences between complete absorption and residuals groups were found in percentages of consolidation (1.5% vs. 13.8%, P=0.010), number of involved lobe >3 (40.0% vs. 72.5%, P=0.030), CT score >4 (20.0% vs. 65.0%, P=0.010) at day 8-14.ConclusionsMost OP cases had good prognosis. Approximately one-third of cases had complete absorption of lesions during 1-2 months after symptom-onset while those with increased frequency of consolidation, number of involved lobe>3, and CT score >4 at week 2 after symptom-onset may indicate lesion residuals on CT.

Sign in / Sign up

Export Citation Format

Share Document